By Michael Dabaie

Teva Respiratory LLC, an affiliate of Teva Pharmaceutical Industries Ltd., said the U.S. Food and Drug Administration has approved ArmonAir Digihaler Inhalation Powder.

The inhaled corticosteroid is delivered by Teva's Digihaler device, which contains built-in sensors and connects to a companion mobile application that provides information on inhaler use to people with asthma.

ArmonAir Digihaler is indicated for the maintenance treatment of asthma in patients 12 years and older, Teva said.

The approval was based on the review of the supplemental new drug application submitted by Teva to the FDA.

Teva ADRs were down 4% premarket to $12.65.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

February 24, 2020 08:58 ET (13:58 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024 Plus de graphiques de la Bourse Teva Pharmaceutical Indu...
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024 Plus de graphiques de la Bourse Teva Pharmaceutical Indu...